Social Security Report

Latest News

Cruelly high cost of drugs in U.S.

We Americans pay more for medicines than almost any other industrialized nation in the world. here are just a few shocking examples of drug company profiteering in recent years, according, in part, to a superb 16-page report and analysis by Medscape Medical News. Imatinib (brand name Gleevec) sold by Novartis to treat chronic myelogenous leukemia, cost in 2001 about $30,000 per year. Imatinib has now tripled in price, retailing for about $90,000. Gleevec has become Novartis’s best-selling drug and brought in about $4.7 billion in 2012….Read More

Notice: The “Read more…” link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; socialsecurityreport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc. or socialsecurityreport.org.